Skip to content

Clinical evaluation of acute effects of Mitragyna speciosa on ocular parameters in regular consumers

Clinical Evaluation of Acute Effects of Mitragyna speciosa on Ocular Parameters in Regular Consumers: A Randomized Double-Blind Placebo-Controlled Crossover Study

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260601006
Enrollment
24
Registered
2026-06-01
Start date
2026-05-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kratom exposure

Interventions

Participants receive kratom tea prepared with 3 grams of kratom tea powder during the first treatment period and placebo tea prepared from Chinese cabbage (Brassica rapa subsp. pekinensis) powder duri
Experimental Drug,Experimental Drug
Kratom-Placebo Sequence ,Placebo-Kratom Sequence

Sponsors

Faculty of Optometry, Siam University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male participants aged 20 to 40 years old 2. Body weight between 50 and 75 kilograms 3. Regular kratom intake 1-3 days per week, 1-2 times per day, with each dose not exceeding 5 g, for a duration of 3 months to less than 3 years.

Exclusion criteria

Exclusion criteria: 1. History of intraocular surgery or eye trauma. 2. History of ocular diseases such as glaucoma, diabetic retinopathy, cataract, keratoconus, or eyelid disorders. 3. History of neurological disorders or use of medications affecting the central nervous system. 4. Known allergy or adverse reaction to kratom consumption. 5. Current use of systemic or topical corticosteroids (oral or ophthalmic). 6. Abnormally high or low blood pressure beyond safe limits. 7. Use of medications metabolized by cytochrome P450 enzymes, including anticoagulants, psychotropic drugs, and opioid analgesics. 8. Presence of insomnia or chronic sleep disorders. 9. History of liver, kidney, or thyroid dysfunction. 10. History of chronic medical condition such as cardiovascular disease, diabetes, cancer, etc.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention Non contact tonometer

Secondary

MeasureTime frame
Anterior chamber angle Anterior chamber depth Anterior chamber volume Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention Oculus Pentacam ,Central corneal thickness Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention WAM 800 open view autorefractor,Pupil size Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention WAM 800 open view autorefractor,Choroidal thickness Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention Optical coherence tomography,Blood pressure and heart rate Baseline, 30 minutes, 60 minutes, and 90 minutes after intervention Automatic blood pressure monitor

Countries

Thailand

Contacts

Public ContactTrinnawat Tongchit

Faculty of Optometry, Siam University

trinnawat.ton@siam.edu0889162359

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026